key: cord-0821655-or18dq4p
authors: Aparecida Takahashi, Jacqueline; Vianna Rodrigues Barbosa, Bianca; Thomaz Nogueira Silva Lima, Matheus; Gomes Cardoso, Patrícia; Contigli, Christiane; Pinheiro Santos Pimenta, Lúcia
title: Antiviral fungal metabolites and some insights into their contributionto the current COVID-19 pandemic
date: 2021-08-13
journal: Bioorg Med Chem
DOI: 10.1016/j.bmc.2021.116366
sha: d718e0a2258d752de83631dbcc92ab6f4f63247b
doc_id: 821655
cord_uid: or18dq4p

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak, which started in late 2019 drove the scientific community to conduct innovative research to contain the spread of the pandemic and to care for those already affected. Since then, the search for new drugs that are effective against the virus has been strengthened. Featuring a relatively low cost of production under well-defined methods of cultivation, fungi have been providing a diversity of antiviral metabolites with unprecedented chemical structures. In this review, we present viral RNA infections highlighting SARS-CoV-2 morphogenesis and the infectious cycle, the targets of known antiviral drugs, and current developments in this area such as drug repurposing. We also explored the metabolic adaptability of fungi during fermentation to produce metabolites active against RNA viruses, along with their chemical structures, and mechanisms of action. Finally, the state of the art of research on SARS-CoV-2 inhibitors of fungal origin is reported, highlighting the metabolites selected by docking studies.

In addition, other viral threats for humankind that afflict restricted groups of individuals or are endemic in specific world regions, have been re-emerging, which is also very concerning because of high lethality, severe side effects, high cost of medicines, and absence of effective vaccines. A relevant issue in the reemergence of viral threats is the intense aerial transportation, migration, and inadequate hygienic-sanitary conditions that contribute to virus dissemination. Hepatitis virus (HV) types A (HAV), B (HBV), C (HCV), D, and E are good examples of major public health concerns, and immediate actions are necessary to achieve the World Health Organization's goal of eliminating the disease as a public health threat by 2030. 9 Acquired Immune Deficiency Syndrome (AIDS) epidemic caused by Human Immunodeficiency Virus (HIV) has become a major concern in the last 40 years, but, in this case, antiretroviral therapy helped to decrease the number of deaths related to HIV. 10 The reemergence of viral diseases is associated with virus genetic flexibility, especially in fast-mutating RNA viruses, giving them the ability to adapt to new hosts and environments, leading to different epidemiological behaviors at local and global levels. 11 These events allied to their anthropogenic causes, 12 together with the underlying processes of virus mutation 11 and adaptation offer good epidemiological models that could help to predict future pandemic reemergence.

In this review, we discuss some antiviral drugs currently available, the activity and structural features of selected fungal metabolites effective against RNA viruses, and the structures of some interesting antiviral fungal metabolites. Some parallels with demands related to COVID-19 medications are also shown. We hope to shed some light on the huge number of fungal metabolites active against emerging and reemerging viruses, especially to pave the way to conquer COVID-19.

Among the initiatives to control the spread of viral diseases and the severity of their effects, the development of new antivirals is critical. In this scenario, drug repurposing has been a useful strategy, since toxicity can be anticipated, and industrial production has already been established. 16 This is the case of two fungal metabolites, cyclosporine A and mycophenolic acid, both previously approved by the US Food and Drug Administration (FDA) as immunosuppressant agents, which became drug candidates against HIV-1, and Vesicular Stomatitis Indiana Virus (VSV). 18 The synthesis of mycophenolic acid derivatives with different functionalities in the aromatic cycle has been reported to overcome side effects and toxicity. 19 Fungal metabolites are also promising for the development of new antiviral drugs. The production of fungiderived metabolites can be scaled up for industrial manufacture of drugs with relatively low production costs compared to the development of synthetic drugs, and some early related fungal metabolites are worth revisiting. For instance, in the 1960s, statolon, a polysaccharide produced by Penicillium stoloniferum, was shown to induce interferon production by murine immune cells in response to Friend Leukemia Virus infection, without strong outcomes at that time. 20 After further studies, statolon is currently listed in a patent as an active antiviral compound. 21 Another example comprises an early reported group of antiviral macrocyclic trichothecene mycotoxins, such as verrucarin A (1) . Although trichothecenes toxicity, verrucarin J (2) is currently being studied as a drug against lung cancer, 22 while verrucarin A (1) has been reported as one of the three top drugs to bind SARS-CoV-2 proteinase in docking studies. 23 Verrucarin J and A toxicity is related to several structural factors, such as the double bond between C9 and C10, the epoxide ring between C12 and C13, the number of oxygen substituents, and macrocycle ester functions In another example, chetomin (3) (Fig. 3) , a diketopiperazine dimer isolated from Chaetomium cristatumis, demonstrated potential for inhibiting VSV 25 and toxicity associated with the sulfide bridge, present in this class of molecules, were initially limiting factors for the development of chetomin-based drugs. Based on structure-activity relationship (SAR) studies, less toxic simplified related compounds have been developed with the epidithiodiketopiperazine moiety present in the natural compound chaetocin (4), such as PSETP-1 (5). 26 Meanwhile, thiodiketopiperazine compounds have been designed and elegantly synthesized using a stereoselective approach, leading to promising antitumor compounds with reduced toxicity. 27 Figure 3 presents the chemical structures of compounds 3, 4, and 5, highlighting the structural features related to antiviral activity (in red) and toxicity (in black and green). Therefore, even fungal metabolites previously discarded from clinical trials, due to toxicity issues, may still become drug leads using techniques such as structural simplification and synthesis of derivatives, to achieve less toxic semi-synthetic analogs. These examples demonstrate the value of a new insight over the state-of-the-art of research on fungal metabolites with antiviral activity, directed toward the discovery of effective new prescription drugs for individuals infected with SARS-CoV-2.

Aside from the fact that the Coronaviridae family has been known for almost five decades, specific treatments concerning drugs or vaccination are emerging for SARS-CoV-2 in 2021. Possible therapeutic targets for COVID-19 depend on the molecular mechanisms underlying viral replication, genome sequencing, and proteome identification. 28 The approach "Breaking the Cycle" (the reproductive cycle) of IAV, HIV, HV, and SARS-CoV-2, based in the diversity of viral families and their specific molecular strategies for host-cell infection and particle replication, has raised important research strategies for treating viral diseases, and it is directing COVID-19 treatment. 29 Viruses are supramolecular complexes of nucleic acids, either DNA or RNA, encapsulated in a protein coat that may contain proteases or polymerases that are necessary for viral replication inside the cell. SARS-CoV-2 particles (Fig. 4 ) are protected by a lipid envelope (E), where several proteins with structural and virulence importance [membrane proteins (M), spike proteins (S), and hemagglutinin esterase] are anchored. 30 Viruses can infect organisms of a broad taxa spectrum, with different tropisms. Viral-host specificity is determined by surface proteins (e.g., spike proteins and host receptors) that trigger the adsorption (virus-host interaction) process. In general, host-cell infection occurs via cell fusion between the host-cell plasma membrane and the viral particle or via receptor-mediated endocytosis with particle internalization (endosome). Untied endosomes allow for the release of viral particles inside the cell. reproduction cycle, from its early stages to virion particle release, is schematically represented in Fig. 5 .

Viral infection begins with a random collision between a viral particle and a potential host cell. Before entering, either via endosomal or membrane fusion, SARS-CoV-2 spike proteins must interact with angiotensin-converting enzyme 2 (ACE2) cell receptors to invade the cell. 31 S-glycoprotein-ACE2 engagement is dependent on the proteolytic activity of cathepsin L, an endosomal endopeptidase, and transmembrane protease serine 2 (TMPRSS) when cell invasion occurs via membrane fusion. S-cleavage into S1/S2 subunits is essential for host cell invasion and genome release (uncoating). 31 ACE2, which is part of the angiotensin vasoconstriction regulatory axis, is abundantly present in lung epithelial cells, and is therefore implicated in the severe patho-respiratory condition of COVID- 19. 32 Once inside the host cell, the viral genome is released. The SARS-CoV-2 genome contains approximately 30,000 nucleotides and encodes for structural (e.g., envelope proteins) and non-structural proteins (e.g., helicases), including a self-RNA replication/transcription complex (RTC). 33 The replicase complex is encoded by a 20 kb gene in the positive-sense single-stranded RNA. In the host-cell cytoplasm, the coronavirus replicase complex gene is translated into two polyproteins, PP1A and PP1AB, which include 16 non-structural proteins. PP1A and PP1AB are edited by SARS-CoV-2 main protease (M pro ), also known as chymotrypsin-like protease (3CL pro ), and papain-like protease (PL pro ). 30 M pro recognizes eleven cleavage points, while PL pro has three predicted cleavage sites over the polyproteins. 34 Genome replication and viral particle assembly are highly dependent on both proteases. The newly synthesized viral protein structural apparatus develops inside the endoplasmic reticulum and the Golgi apparatus, and sends to progeny assembly, together with genome replicates, providing novel virion particles that are released via exocytosis. 35 Most of them are prompted by plasma membrane depolymerization, which can be completely 

Because of the importance of viral proteases for the transcription and replication of Coronavirus, this family of proteins has been considered as a potential target in new drug design. 37 The SARS-CoV-2 M pro crystal structure, published in March 2020, 38 details the substrate-binding pocket (Fig. 6 ) and target amino acid residues for antiviral design. M pro is a 3-domain (DI, DII, and DIII) autolytic endopeptidase and its structure and sequence are conserved among identified coronaviruses, exclusively related to the Coronaviridae family. 34 The genome of SARS-CoV-2 has 82% similarity to its closest betacoronavirus, SARS-CoV, and M pro holds 96% sequence identity. DI and DII hold the chymotrypsin catalytic gorge, including His41 and Cys145 residues, while DIII N-terminal residues promote homodimerization. 38 In contrast to SARS-CoV M pro , SARS-CoV-2's M pro homodimer does not present a hydrophobic interaction between DIII homodimers, due to a substitution of Thr285 and Ile286 residues to alanine and leucine, respectively, enhancing proteolytic activity. 38 At the same time, these SARS-CoV-2 peculiarities create prominent targets in drug design and development, possibly helping COVID-19 combat. 

From 1963 to 2016, 90 drugs were formally approved for the treatment of human viruses, eleven of which had broad coverage. Eight antiviral drug classes act on viral metabolic pathways: entry inhibitors, nucleoside and non-nucleoside reverse transcriptase, protease, integrase, acyclic nucleoside phosphonate, pyrophosphate, and 5-substituted 2'-deoxyuridine analogs. Some drugs target more specific proteins in the cells, such as HCV acyclic guanosine analogs, NS5A/NS5B, neuraminidase, and polymerase inhibitors.

Other strategies do not directly target viral proteins, such as interferon immune stimulators, oligonucleotide analogs, and antimitotic inhibitors. 39 The The second class of antivirals involves inhibitors of viral genome release (inhibitors of viral uncoating).

The first drug approved in this class was amantadine (9), followed by rimantadine and derivatives, but the widespread viral resistance prevented their further utilization. 43 A bicyclam named JM2763 (10) and the natural products hypericin (11) and pseudohypericin act in the uncoating process. 44 Nucleoside and non-nucleoside reverse transcriptase inhibitors, which interfere with the multiplication of the viral genome, are the third and fourth classes of antiviral drugs. After the virus enters the host cell, it begins to copy itself. Retroviruses need to copy their RNA into DNA, a process called reverse transcription, mediated by a reverse transcriptase enzyme, that can be inhibited by nucleoside-resembling molecules, called nucleosides reverse and non-nucleoside reverse transcriptase inhibitors. 45 The late are remarkably effective antivirals and, currently, there are six drugs approved by the FDA commercially available: was attributed to the β-hydroxyl group present in its structure. 67 The screening of fungi from niches such as Antarctica is supported by the metabolic differentiation in fungal biosynthesis necessary for survival under drastic climatic conditions. This behavior was observed for the Antarctic species Aspergillus ochraceopetaliformis (SCSIO 05702), which produces ochraceopone A (34), a linear tetracyclic α-pyrone merosesquiterpenoid with a new skeleton, along with isoasteltoxin (35) and asteltoxin (36) . These compounds effectively inhibited the cytopathic in vitro effect of IAV H1N1 and H3N2 strains. 68 The structures of metabolites 20-36 are shown in Fig. 8 . 

The adaptive ability of fungi to different fermentation protocols, upon alteration of parameters such as carbon and nitrogen sources, availability of macro and micronutrients, pH, fermentation length, and temperature variation, can be exploited in the production of new antiviral metabolites. Rice is frequently reported as a substrate for the production of fungal metabolites 69 (Table 2) , although reproducibility in rice-based culture medium should be carefully evaluated, considering commercial variation. The cultivation length can be as short as six 70 or more than seventy days. 71 Table 2 shown in Fig. 9 .

Measurement of medium depletion can determine the fermentation stop-point, an approach used by Narmani et al. 79 during the recovery of prenylated p-terphenyl quinine metabolites from Cytospora sp.

However, fermentation length does not follow a restrictive unique rule regarding productivity, as exemplified by experiments with Scedosporium apiospermum (40 days; 0.22 g l -1 yield), 72 Phoma sp. (11 days; 1.1 g L -1 yield), 74 and Simplicillium obclavatum (30 days; about the same yield, 1.09 g L -1 ). 80 In most studies cited herein, metabolite isolation usually started using silica gel vacuum liquid chromatography, followed by a Sephadex LH20 column, 71 

Nevertheless, the purification of fungal metabolites in research laboratories for antiviral screening can become a game of patience. During the development of new drugs, low yields can be overcome using bench-size bioreactors and genetic manipulation. 82 Detection of the major compounds present in crude extracts, before the isolation step, is useful to direct the efforts, optimize time-consuming purification processes, and avoid re-isolation of known compounds. Nuclear Magnetic Resonance (NMR)-directed isolation is very effective in targeting specific classes of compounds in crude extracts or fractions. In this approach, the isolation step is monitored by NMR, and only extract/fractions with chemical shifts related to the target compounds are further purified or assayed, as successfully demonstrated during the isolation of allenyl (54-56) and alkynyl truncateols O (57) and P (50) from Truncatella angustata. 75 Metabolome analysis by Liquid Chromatography coupled to High-Resolution Mass Spectrometry (LC-HRMS) 80 to the culture medium led to the production of three formamides and 18 quinazoline-containing indole alkaloids. A metabolite bearing a rare pyrazinoquinazolinedione, scedapin C (39) and a new scequinadoline alkaloid (40) 

In the aforementioned examples, the initial step of the prospective studies to detect antiviral metabolites from fungi usually consisted of in vitro screening of potential leads, starting from the assessment of cytotoxic and side effects on host cells in culture assays. After preliminary results, the selected molecules should be targeted by mechanism-directed assays. Standardized protocols and commercial kits for biochemical or cell-based assays are important resources for determining viral replication, cell viability and cytotoxicity, or specific metabolic and signaling pathways, ensuring reproducibility and allowing bench or high-throughput screening of potential antiviral compounds. 86 The quantity of viral proteins and reduction of viral nucleic acids in infected cells have been measured in assays against non-cytopathic viruses. Polymerases are essential for all viruses and are excellent targets for antiviral therapies; therefore, quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) has been the preferred method for monitoring the activity of DNA polymerases (cellular or viral) in the presence of inhibitors, 89 and has become a standard model for screening viral RNA polymerase inhibitors. 90 Quantitative detection can be achieved using a wide variety of sequence-specific probes or non-specific fluorescent dyes that bind to the genetic material. Mugisha et al. 51 proposed a simplified and efficient method to detect viral RNA in cell culture supernatants, to reduce the costs of qRT-PCR used to monitor the response of SARS-CoV-2 to potential antivirals.

Additionally, computer-aided drug design has been widely utilized in the search for antiviral agents, because it is a reliable, fast, sustainable, and cheap approach compared to wet-lab testing. Tridimensional molecular models of candidate molecules and/or molecular targets can be built and studied in silico under different conditions, and the results are statistically processed. This strategy can be directed to the receptor (structure-based drug design) or ligand (ligand-based drug design) depending on a series of factors and data availability. 91 Many studies have used structure-activity relationship (SAR) tools to identify potentially bioactive metabolites and to plan the synthesis of derivatives bearing antiviral pharmacophoric groups. This approach led to the identification of exocyclic double bond and oxidation on specific groups as key structural features related to the inhibition of HIV-1 cellular infection by eight armochaetoglobins isolated from the symbiotic fungus Chaetomium globosum TW1-1. 92 Likewise, the inhibit the cytopathic effect of IAV H1N1 (A/WSN/33 strain) was associated by SAR with specific substituents at the diketopiperazine moiety of rubrumline D (58) and other related metabolites, isolated from marine-derived Eurotium rubrum F33. 93 The positive effect of alkynyl groups in activity enhancement, reported for truncateols O and P (57 and 50) (Fig. 10) , metabolites isolated from the fungi species T. angustata, were successfully pointed by SAR studies. 75 The low cytotoxicity of these truncateols compared to the positive control used in the work, efavirenz (13), an antiretroviral drug prescribed for patients with HIV-1, encourages further studies on this class of compounds.

SAR is also important for the synthesis of analogs, as shown in the stereoselective synthesis of reubrolides R and S (59 and 60) , where SAR directed the introduction of a β-aryl substituent at a late stage of the synthesis, aiming at the preparation of antiviral compounds. 94 In the synthesis field, click-chemistry and modern fluorescence microscopy techniques together allow site-specific design of new molecules, based on the interaction of host cells and viral factors, and seems very promising in the near future. 95 Multi-target and in silico screenings are advantageous over single strain-directed assays, as a fungal species can produce metabolites that are active against different viruses. For example, three compounds isolated from a marine-derived species of Penicillium sp. were screened to assess the relative inhibition of three viruses (HIV-1, IAV H1N1 and HCV) . One of the compounds, trypilepyrazinol (61) demonstrated in vitro protective effects against HIV-1 and HCV. Trypilepyrazol is a new polyketide derivative that contains a pyrazine heterocycle, an important pharmacophore found in many bioactive drugs, as part of its structure.

The other two compounds, (+)-neocitreoviridin (62) and a new ergostane analogue (63) presented a different behavior, being active against IAV H1N1. 69 The different selectivities of metabolites 61, 62, and 63 were only observed because different viruses were included in the experimental protocol. On the other hand, some metabolites present broad antiviral activity, as reported for brefeldin A (38) (Fig. 9) , isolated from Penicillium sp. FKI-7127, which selectively inhibited four Filipino patient-derived DENV strains and ZIKV (strain 976) once subjected to a multi-target antiviral assay. 70 The structures of metabolites 54-64 are shown in Fig. 10 .

Resistance is a major problem that must be taken into consideration in antiviral screening to develop drugs that are effective also against resistant strains. In this context, the fungal metabolite neoechinulin B (64), produced by E. rubrum F33, was tested against IAV, a virus resistant to commercial drugs such as ribavirin Overall, the chemical structures of antiviral drugs 6-19 are diversified enough to selectively target RNA viral proteins according to their respective mechanisms of action. Pharmacophore-based approaches are among the current protocols for repurposing drugs as SARS-CoV-2 inhibitors. Using this approach, compounds bearing indoloquinoline, benzimidazole, indolyl, and carbamate moieties were among the five top drugs with higher docking scores to inhibit viral M pro . 96 In the same way, antiviral fungal metabolites also feature high chemical diversity, including heterocyclic diazo scequinadoline A (37), macrocycle brefeldin A (38) , and anthraquinones (44 and 45). There are some similarities among the structures of the antiviral drugs (Fig. 7) and antiviral fungal metabolites (Fig. 8-11 ). Fungal metabolites chetomin ( 

In the worldwide efforts to find an effective treatment for COVID-19, several FDA-approved drugs, from distinct natural sources or synthetically designed, are being evaluated for their interaction with SARS-CoV- The high affinity of etravirine, rilpivirine, and nevirapine (12) for the SARS-CoV-2 protease active site was also revealed by molecular docking studies, and nevirapine (12) presented a higher IC 50 (half-maximal inhibitory concentration) for SARS-CoV-2 than for HIV protease. 54 Docking simulations directed to drug repurposing spare time and resources, since prescription drugs have already passed the initial clinical and toxicity trials. 50, 54, [104] [105] [106] [107] Likewise, a number of fungal natural compounds have been identified as interesting starting points for the development of COVID-19 therapeutic agents, as indicated by computational studies and preliminary in vitro assays. [100] [101] [102] [106] [107] [108] [109] [110] [111] [112] [113] Based on their similarities to the non-nucleoside reverse transcriptase inhibitor efavirenz (13), considered a repurposing drug candidate for COVID-19 treatment, 23 the FDA-approved metabolite podophyllotoxin isolated from endophytic fungi, 114 lovastatin (a well-known fungal metabolite) and its derivative simvastatin were evaluated for their interaction with SARS-CoV-2 proteins, using virtual screening, molecular docking, and density functional theory, with promising results. 106 Table 3 (Table 3 , Fig. 11 ). The same approach was applied in another study, with a larger number of metabolites from different taxa, pointing to three other fungal compounds, jasmonic acid (67) and putaminoxin D (68), as potential inhibitors of M pro , with favorable ADMET properties. 108

Cordycepin (69) is a secondary metabolite produced by Cordyceps militaris, with a broad spectrum of biological activities, including antiviral action. 115 Molecular interaction simulations revealed its high binding affinity to both SARS-CoV-2 M pro and spike protein binding sites. 107, 109 Moreover, this molecule has a remarkable similarity to adenosine, indicating an additional role in inhibiting the poly(A) polymerase, which is essential for 3'-polyadenylation of viral RNAs like SARS-CoV-2. 107 Pharmacology network predictions also reinforce the potential role of cordycepin (69) (79), as anti-inflammatory agents, 113, [118] [119] [120] indicating their possible effect on protecting patients from severe inflammation induced by SARS-CoV-2 infection. 33 Indeed, quercetin (82) is the focus of several studies to evaluate its effect on prophylaxis and or treatment for COVID-19, according to WHO ICTRP and ClinicalTrials.gov databases (Fig. 12) . 

Fungi have long been known as sources of metabolites with great diversity, and many them exhibit activity against diverse human emerging and reemerging pathogenic viruses. The "arsenal" of candidate molecules produced by fungi, with a broad spectrum of antiviral activities, encourages continuous efforts to explore the potential of this chemical library in drug discovery programs. SARS-CoV and MERS-CoV, as well as the potential of coronaviruses to cause epidemics, emphasizes the need for novel drugs to treat CoV infections associated with immunization programs. The use of technological approaches to diversify fungal metabolic pathways, automated pharmacological testing, computational molecular design and docking have been guiding further in vitro and in vivo studies to find suitable drug leads against viruses. In these multidisciplinary scenarios, fungal metabolites are promising sources of compounds that can interfere with different targets of virus life cycles, as shown in some ongoing studies searching for drugs to fight SARS-CoV-2 infection. 112 Flammulina velutipes

Binding affinity to M pro Non-toxic, non-carcinogenic, non-mutagenic

In silico molecular docking analysis and ADMET predictions

Protease inhibitors are also the main targets of HCV infection. For instance, ribavirin (18) (Copegus, Roche) targets viral RNA polymerase, and is effective against five viruses

Janssen-Cliag Pharmaceutica) and simeprevir (OLYSIO, Janssen-Cliag Pharmaceutica) have been reported to have better response rates, although they are more expensive. 44,53 Oseltamivir (19) (Tamiflu, Gilead Sciences), zanamivir (Relenza, GSK), and peramivir (Rapivab, Biocryst Pharmaceuticals) target viral neuraminidases or mRNA synthesis

Prioritizing diseases for research and development in emergency contexts

2021. WHO Coronavirus (COVID-19) Dashboard

COVID-19 vaccine tracker and landscape

Covid-19 Vaccine Tracker. Regulatory Affairs Professionals Society

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

Q&A Detail/Coronavirus disease (COVID-19): Vaccines. Is there a vaccine for COVID-19?

Notable and Emerging Variants of SARS-CoV-2 Virus: A Quick Glance

Evolving biothreat of variant SARS-CoV-2 -molecular properties, virulence and epidemiology

WHO -World Health Organization

Modeling the HIV epidemic: Why the 95-95-95 target and ART effectiveness parameters matter

Mechanisms of viral mutation

Viroses emergentes e reemergentes

The history of dengue outbreaks in the Americas

Dengue serotype-specific differences in clinical manifestation, laboratory parameters and risk of severe disease in adults

West Nile virus infections spike in southern and central Europe

WHO -World Health Organization

Drug repurposing for new, efficient, broad spectrum antivirals

Mycophenolic acid: Biogenesis, compound isolation, biological activity, and historical advances in total synthesis

Prolongation of life in mice with established Friend Virus Leukemia by inoculation with Sendai virus, interferon, or statolon

Prevention and treatment of viral infections

United States Patent 10

Targeting of lung cancer stem cell self-renewal pathway by a small molecule verrucarin

Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

The ribosome-binding mode of trichothecene mycotoxins rationalizes their structure-activity relationships

Cristazine, a new cytotoxic dioxopiperazine alkaloid from the mudflat-sediment-derived fungus Chaetomium cristatum

Epidithiodiketopiperazine as a pharmacophore for protein lysine methyltransferase G9a inhibitors: Reducing cytotoxicity by structural simplification

Synthesis of potent cytotoxic epidithiodiketopiperazines designed for derivatization

SARS-CoV-2 and viral sepsis: observations and hypotheses

The sprint to solve coronavirus protein structures -and disarm them with drugs

Genotype and phenotype of Covid-19: Their roles in pathogenesis

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Renin-angiotensin system at the heart of Covid-19 pandemic

Genomic characterization of a novel SARS-CoV-2

Structure of M pro from SARS-CoV-2 and discovery of its inhibitors

Coronavirus biology and replication: implications for SARS-CoV-2

Cell cycle regulation during viral infection

Natural bioactive compounds from fungi as potential candidates for protease inhibitors and immunomodulators to apply for coronaviruses

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Approved Antiviral Drugs over the Past 50 Years

Modeling and spectroscopic studies of synthetic diazabicyclo analogs of the HIV-1 inhibitor BMS-378806 and evaluation of their antiviral activity

Maraviroc: the first chemokine coreceptor 5 inhibitor

A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity

Antiviral drugs for viruses other than human immunodeficiency virus

Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event

Doravine: Researchers DRIVE for a drug ahead of its class

Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses

Recent discoveries in HIV-1 reverse transcriptase inhibitors

Natural bioactive compounds from fungi as potential candidates for protease inhibitors and immunomodulators to apply for coronaviruses

Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme

Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2

A simplified quantitative real-time PCR assay for monitoring SARS-CoV-2 growth in cell culture

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Antiviral perspectives for Chikungunya virus

In silico identification of clinically approved medicines against the main protease of SARS-CoV-2, causative agent of Covid-19

Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019

Breviane spiroditerpenoids from an extreme-tolerant Penicillium sp. isolated from a deep-sea sediment sample

Enantiocontrolled total syntheses of breviones A, B, and C

From oxiranes to oligomers: Architectures of U.S. FDA approved pharmaceuticals containing oxygen heterocycles

Strategies for the synthesis of furo-pyranones and their application in the total synthesis of related natural products

Cladosins A-E, hybrid polyketides from a deep-sea-derived fungus, Cladosporium sphaerospermum

Total Synthesis of Cladosins B and C

Antiviral meroterpenoid rhodatin and sesquiterpenoids rhodocoranes A-E from the wrinkled peach mushroom, Rhodotus palmatus

Bioactive hydroanthraquinones and anthraquinone dimers from a soft coral-derived Alternaria sp. Fungus

Antiviral anthraquinones and azaphilones produced by an endophytic fungus Nigrospora sp. from Aconitum carmichaeli

A new antiviral 14-nordrimane sesquiterpenoid from an endophytic fungus Phoma sp

New azaphilones, phomopsones A-C with biological activities from an endophytic fungus Phomopsis sp. CGMCC No.5416

Carneic acids from an endophytic Phomopsis sp. as Dengue virus polymerase inhibitors

Antiviral merosesquiterpenoids produced by the antarctic fungus Aspergillus ochraceopetaliformis SCSIO 05702

Broad-spectrum antiviral natural products from the marine-derived Penicillium sp. IMB17-046

Identification of novel antiviral of fungus-derived brefeldin A against dengue viruses

Polyketides and alkaloids from the marine-derived fungus Dichotomomyces cejpii F31-1 and the antiviral activity of scequinadoline A against Dengue virus

Amino acid-directed strategy for inducing the marine-derived fungus Scedosporium apiospermum F41-1 to Maximize Alkaloid Diversity

Asteltoxins with antiviral activities from the marine sponge-derived fungus Aspergillus sp. SCSIO XWS02F40. Molecules

Structurally diverse sesquiterpenoids and polyketides from a spongeassociated fungus Aspergillus sydowii SCSIO41301

Truncateols O-V, further isoprenylated cyclohexanols from the sponge-associated fungus Truncatella angustata with antiviral activities

L-tryptophan induces a marine-derived Fusarium sp. to produce indole alkaloids with activity against the Zika virus

The natural product cavinafungin selectively interferes with Zika and Dengue virus replication by inhibition of the host signal peptidase

Cyclic colisporifungin and linear cavinafungins, antifungal lipopeptides isolated from Colispora cavincola

Cytotoxic, antimicrobial and antiviral secondary metabolites produced by the plant pathogenic fungus Cytospora sp. CCTU A309

Antifungal and antiviral cyclic peptides from the deepsea-derived fungus Simplicillium obclavatum EIODSF 020

Determination of lead in drinking water by icp-aes with ultrasonic nebulization and flow-injection on-line preconcentration using an amberlite xad-16 resin

Recent Developments in Bioprocessing of Recombinant Proteins: Expression Hosts and Process Development

Exploring the antibacterial activity of Pestalotiopsis spp. under different culture conditions and their chemical diversity using LC-ESI-Q-TOF-MS

Production and new extraction method of polyketide red pigments produced by ascomycetous fungi from terrestrial and marine habitats

Bioactivity-based molecular networking for the discovery of drug leads in natural product bioassay-guided fractionation

Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains

Organ-on-a-chip technology: turning its potential for clinical benefit into reality

Global trends of organoid and organ-on-a-chip in the past decade: a bibliometric and comparative study

Fluorescence-based DNA polymerase assay

Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis

Ensemble docking in drug discovery

Armochaetoglobins K-R, anti-HIV pyrrole-based cytochalasans from Chaetomium globosum TW1-1

Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin

Concise, stereocontrolled and modular syntheses of the anti-influenza rubrolides R and S

A spotlight on viruses-application of click chemistry to visualize virus-cell interactions

Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M pro

Indole -a promising pharmacophore in recent antiviral drug discovery

Rational design of potent sialidase-based inhibitors of influenza virus replication

Nelfinavir Mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease

A computer-aided drug design approach to predict marine drug-like leads for SARS-CoV-2 main protease inhibition

Proposing a fungal metabolite-flaviolin as a potential inhibitor of 3CL pro of novel coronavirus SARS-CoV-2 identified using docking and molecular dynamics

Reckoning a fungal metabolite, pyranonigrin A as a potential main protease (M pro ) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation

Supercomputer-based ensemble docking drug discovery pipeline with application to Covid-19

Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB

In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2

Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz

Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm

ADMET profile and virtual screening of plant and microbial natural metabolites as SARS-CoV-2 S1 glycoprotein receptor binding domain and main protease inhibitors

Cordycepin: a bioactive metabolite of Cordyceps militaris and polyadenylation inhibitor with therapeutic potential against Covid-19

Virtual screening-driven drug discovery of SARS-CoV2 enzyme inhibitors targeting viral attachment, replication, post-translational modification and host immunity evasion infection mechanisms

Flavonoids and nucleotide analogs show high affinity for viral proteins of SARS-CoV-2 by in silico analysis: New candidates for the treatment of Covid-19. Res Sq

Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An in silico approach

Ergosterol peroxide from an edible mushroom suppresses inflammatory responses in RAW264.7 macrophages and growth of HT29 colon adenocarcinoma cells

Endophytes for production of podophyllotoxin. Unites States Patent US20040248265A1

Cordycepin, an adenosine analogue executes anti rotaviral effect by stimulating induction of type I interferon

Structural stability of SARS-CoV-2 3CL pro and identification of quercetin as an inhibitor by experimental screening

Discovery of naturally occurring inhibitors against SARS-CoV-2 3CL pro from Ginkgo biloba leaves via large-scale screening

Ergosterol ameliorates renal inflammatory responses in mice model of diabetic nephropathy

Anti-inflammatory potential of Quercetin in Covid-19 treatment

Quercetin efficiently alleviates TNF-αstimulated injury by signal transducer and activator of transcription 1 and mitogen-activated protein kinase pathway in H9c2 Cells: A protective role of quercetin in myocarditis

Bharat Biotech + India's National Institute of Virology ICMR + Ocugen + ViroVax

Non-replicating recombinant adenovirus vector (rAd26 and rAd5

CanSino Biologics (China) + Beijong Institute of Biotechnology Argentina

Johnson & Jonhson)

Table 2 Examples of fungal metabolites, activity against DENV, HV, H1N1, HIV, and ZIKV, and fermentation conditions

EC 50 4.73 μM [DENV 2 strain 16,681] Sea salt (30 g.L -1 , glucose (20 g.L -1 ), peptone (5 g.L -1 ), yeast extract, L-Phe and D, L-Trp (2 g.L -1 each

Penicillium sp

Soluble starch 3%, glycerol 1.0%, soybean meal 2%, dry yeast, KCl, CaCO 3 , KH 2 PO 4

L -1 ), peptone (5 g.L -1 ), yeast extract (2 g.L -1 )

g), sea salt (2.5 g) 200 mL water

Aspergillus sydowii SCSIO41301 [sponge Phakellia fusca, collected from the Xisha Islands, China] 74 2-Hydroxy-1-(hydroxymethyl

glucose and monosodium glutamate (10 g.L -1 each), KH 2 PO 4 (0.5 g.L -1 )

Human Immunodeficiency Virus (HIV) Phomopsis sp. CGMCC No.5416 [fresh stems of Achyranthes bidentata collected from Nan Ling County

Phomopsone A (48) IC 50 0.5 μM

Rice (80 g 100 mL -1 water) [28 °C

Penicillium sp

Truncatella angustata XSB-01-43 [Reef-finger sponge Amphimedon sp. collected in Yongxing Island

51) 1,2-bis(1H-indol-3-yl)ethane-1,2-dione (52)

L -1 , FeSO 4 ·7H 2 O 20 mg.L -1 , ZnSO 4 ·7H 2 O 20 mg.L -1 ) [22 °C, 21 days, static] M pro and viral RNA polymerase,drug-like ADMET properties In silico molecular docking analysis, ADMET predictions S protein = SARS-CoV-2 spike protein; M pro = SARS-CoV-2 main protease, also known as 3CL pro = SARS-CoV-2 chymotrypsin-like protease

RdRp = RNA-directed RNA polymerase; nsp15 = non-structural protein 15

ADMET = absorption, distribution, metabolism, excretion, and toxicity

QSAR = quantitative structure-activity relationship

HIGHLIGHTS Many fast-spreading viral diseases are uncontrolled causing thousands of deaths worldwide Fungi produce antiviral metabolites with diversified and unprecedented chemical structures Fungal biosynthesis can inspire the discovery of new antiviral drugs Some fungal metabolites are already

The authors gratefully acknowledge the financial support from Fundação de Amparo à Pesquisa do Estado 

JAT proposed the review topic. All authors participated in drafting, critically revised, read and approved the final submitted version. BVRB, LPSP and JAT draft and revised the chemical structures. MNSL drew figures 4-6.☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jacqueline Aparecida Takahashi